Bruno Coelho - stock.adobe.com Lung cancerBayer targets leading position in HER2-positive NSCLCThe potential blockbuster HER2 tyrosine kinase inhibitor sevabertinib, developed jointly by Bayer AG and the Broad Institute, is expected to be submitted for regulatory approval in China in Q3 2025 for … more ➔
Gerd Altmann/pixabay.comAcquisitionFrom Brisbane to London to Paris: Vicebio´s Sanofi dealFrom Brisbane to London to Paris: Australian vaccine innovation sparks US$1.15 billion deal with french Sanofi with an additional US$450 million tied to clinical milestones and underscoring a major commitment … more ➔
Abivax SAColitis UlcerosaAbivax soars 500% on TOP-Line dataIn a watershed moment for both patients and investors, shares in Abivax (Euronext Paris: ABVX / Nasdaq: ABVX) skyrocketed by a staggering 500% following the announcement of positive Phase 3 results from … more ➔
AstraZenecaAstraZenecaWestwards: AstraZeneca Shifts Gears with $50 Billion US InvestmentAstraZeneca announces a US$50 billion investment in the USA amid pharma’s transatlantic drift. Virgina is set to become the multi-billion-dollar drug manufacturing hub. more ➔
Carbios SAPET bio-recyclingCarbios is back with a partnership in the automotive tyre industryFrench CARBIOS SA signs strategic agreement with Indorama Ventures and Michelin amid broader company transition and sees itself back on track. Before opening of its production plant (delayed to later … more ➔
Jovanche Vitanovski/123rf.comCancerOne Bioscience raises €15m to leverage AI tumour profilingParis-based One Biosciences, a pioneering “techbio” company at the intersection of artificial intelligence and oncology, has announced a €15 million Series A funding round to accelerate the clinical … more ➔
Vedran Vukoja AKA vepar5, stock.adobe.comUnited KingdomBold UK-Strategy in Life SciencesThe UK Government launched a ten-year Life Sciences Sector Plan to drive innovation and health reform within the NHS. This Life Sciences Sector Plan is part of its broader Industrial Strategy. more ➔
Axxam S.p.APreclinical target validationClinical data meet preclinical validation: Axxam´s partnership with Molecular HealthThat deserves a closer look: The recently announced partnership between Axxam S.p.A., a leading provider of integrated early discovery services, and Molecular Health GmbH, a pioneer in AI-powered data … more ➔
Oncomatryx Biopharma S.L.Antibody-Drug-ConjugateOncomatryx Secures EU Funding to Advance Antibody-Drug Conjugate PlatformSpanish biotechnology company Oncomatryx Biopharma has been selected for funding under the European Innovation Council (EIC) Accelerator, part of the EU’s Horizon Europe 2021–2027 Research and Innovation … more ➔
David_SMC from PixabayAcquisitionVerona Pharma: A Transatlantic Success Story in the Biotech LandscapeThe planned US$10 billion acquisition of UK-based Verona Pharma by US pharmaceutical giant Merck & Co. underscores several key dynamics reshaping the global biotech industry. Not only does the deal reflect … more ➔
Bruno Coelho - stock.adobe.com 
Gerd Altmann/pixabay.com
Abivax SA
AstraZeneca
Carbios SA
Jovanche Vitanovski/123rf.com
Vedran Vukoja AKA vepar5, stock.adobe.com
Axxam S.p.A
Oncomatryx Biopharma S.L.
David_SMC from Pixabay